Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid's Q1 Revenue Jumps 27 Percent; Clinical Market Becoming 'Key Driver'

NEW YORK (GenomeWeb News) — Cepheid today said first-quarter revenues increased 27 percent as R&D spending rose 19 percent and profit declined around 6 percent.
 
Total receipts for the three months ended March 31 increased to $25.5 million from $20.1 million year over year.
 
Cepheid said instrument sales rose around 50 percent to $.8 million; reagent and disposable sales increased 3 percent to $15.2 million; contract revenues nearly tripled to $1.9 million; and government and government-sponsored research revenue rose five-fold to $1.6 million. The company said clinical products more than doubled to $7.43 million.
 
Cepheid CEO John Bishop said the clinical market is “emerging as the key driver to the growth of our business with a substantial level of opportunity.” Bishop added that the company expects its industrial and biothreat markets to “provide a continuing base of sales but growth rates will likely vary.”
 
R&D spending rose to $6.9 million from $5.8 million year over year.
 
The company said first-quarter profit fell to $6.2 million from $6.7 million in the year-ago period.
 
Cepheid said it had around $7.8 million in cash and cash equivalents, and $45.8 million in marketable securities.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.